Medera
- Biotech or pharma, therapeutic R&D
Medera (www.medera.bio) is a private clinical-stage biopharmaceutical company focused on treatments for severe cardiac diseases through next-generation AAV gene therapy. Founded in 2014 by world-renowned experts in cardiac cell and gene therapy from Johns Hopkins and Mass General Brigham, the Company is focused on developing treatments for both prevalent and orphan cardiac diseases. Our pipeline is comprised of three clinical programs in Phase 1/2 for heart failure with preserved ejection fraction (HFpEF), heart failure with reduced ejection fraction (HFrEF) and Duchenne muscular dystrophy associated cardiomyopathy (DMD-CM) with compelling human proof-of-concept data.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}